Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Also, suppression of miR‑122‑5p significantly reduced AFP levels and proliferation in AFPGC through an induction of apoptosis.
|
30816512 |
2019 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
AFP potentiated growth and aggression in GC cell lines and their derived xenografts.
|
30809100 |
2019 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
ANGPTL6-mediated angiogenesis promotes alpha fetoprotein-producing gastric cancer progression.
|
31146977 |
2019 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, the present case suggests that AFP and HER2 positive gastric cancer can be effectively treated with, capecitabine, cisplatin, and trastuzumab combination therapy.
|
29174919 |
2018 |
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Plasma <i>miR-122-5p</i> expression levels were also significantly higher in the AFPGC patients than the health volunteers and the non-AFPGC patients (<i>P</i> < 0.05) and were strongly correlated with plasma AFP levels (<i>r</i> = 0.7975, <i>P</i> < 0.0001).
|
30364858 |
2018 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
Multimodality Treatment Including Triplet Regimen as First-Line Chemotherapy May Improve Prognosis of Serum AFP-Elevated Gastric Cancer with Liver Metastasis.
|
29434637 |
2017 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
We reported on an extremely rare case of GHAC resulting in a spontaneous gastric perforation and reviewed the literature, including epidemiological data, treatment regimens, and the association between GHAC and alpha-fetoprotein-producing GC.
|
28545511 |
2017 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
Clinicopathologic and prognostic characteristics of alpha-fetoprotein-producing gastric cancer.
|
28423604 |
2017 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
Efficacy and safety of SOX chemotherapy with or without surgery in AFP-producing advanced gastric cancer.
|
28693208 |
2017 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, novel characteristics of AFP-producing GC such as other biomarkers are to be explored.
|
29254216 |
2017 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
Alpha-fetoprotein (AFP)-producing gastric cancer (AFPGC) is a relatively rare type of gastric cancer characterized by a high incidence of liver and lymph node metastases, and a poor prognosis.
|
28928842 |
2017 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
The present study aimed to explore the role and possible mechanism of AFP in the invasion and metastasis of GC AGS cells, particularly in the anoikis sensitivity of AGS cells.
|
26986949 |
2016 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
To investigate the relationship between the serum levels of CEA, CA19-9, CA24-2, CA72-4, and AFP in patients with gastric cancer (GC) and their clinicopathological characteristics; to analyze the efficacy of these tumor markers in evaluating the prognosis of GC.
|
23787496 |
2013 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
Antibody-based assays for hCE1 and AFP were used to test both biomarkers with respect to diagnostic efficiency, Youden's index and the area under the curve (AUC) through receiver operating characteristic (ROC) analysis in plasma from 208 patients with HCC (n=57), liver cirrhosis (n=27), chronic hepatitis (n=37), cholangiocarcinoma (n=22), gastric cancer (n=31) and pancreatic cancer (n=34), along with 52 healthy donors (HDs).
|
23319432 |
2013 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
Survival of patients with gastric cancer was lower with AFP and STAT3 double overexpression than with overexpression of either alone.
|
23382965 |
2013 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
CTD_human |
Downregulation of AFP and STAT3 expression plays an important role in As(2)O(3)-induced apoptosis of AFPGC cells, which suggests a new mechanism of As(2)O(3)-induced cell apoptosis.
|
23382965 |
2013 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
Differences between AFP-producing gastric cancer and common-type gastric cancer in terms of the mechanism of GATA4 regulation may be reflected in the phenotypic deviation of AFP-producing gastric cancer from common-type gastric cancer.
|
22472323 |
2012 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that genetic alteration of the ATBF1 gene may contribute to the aggressive nature of gastric cancers and the production of AFP in gastric cancer cells.
|
17671116 |
2007 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therapeutic application of the AFP enhancer/promoter-specific transfer of the HSVtk gene followed by GCV administration against AFP-producing gastric cancer deserves attention and further research.
|
14666679 |
2004 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
To investigate this further, we established an AFP-producing gastric cancer cell line, designated as AME-1, from the primary tumor of a patient with AFP-producing gastric cancer.
|
14745610 |
2004 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
To investigate the genetic events underlying the phenotypic diversity in AFP producing gastric cancer and the ability of these tumours to produce AFP ectopically.
|
14645355 |
2003 |
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our data suggests that the absence of ATBF1 is responsible for AFP gene expression in gastric cancer, and the absence of ATBF1 is a distinct characteristic of AFP-GC and might be important for its highly malignant nature.
|
11314020 |
2001 |